Cellectis is undergoing a significant business transformation, moving from CAR T cell therapies to in vivo gene editing. This strategic pivot is expected to result in substantial job cuts, potentially impacting up to 70% of its global workforce. The company has ceased enrollment in its existing CAR T programs to concentrate on its in vivo candidates. These layoffs are anticipated to occur throughout the remainder of the year and into 2027. Cellectis aims to fund its operations through the second half of 2028 with its current cash reserves.
https://www.fiercebiotech.com/biotech/cellectis-will-shed-70-workforce-part-vivo-pivot